DMN.F · Diamyd Medical AB (publ)

-

Please sign in to comment on DMN.F

1 Comment

Admin

3 years, 7 months ago

Diamyd Medical AB (publ) is currently in a long term uptrend where the price is trading 6.5% above its 200 day moving average.

From a valuation standpoint, the stock is 466.2% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7437.7.

Diamyd Medical AB (publ)'s total revenue sank by 97.9% to $1K since the same quarter in the previous year.

Its net income has dropped by 59.4% to $15M since the same quarter in the previous year.

Finally, its free cash flow fell by 141.3% to $-15M since the same quarter in the previous year.

Based on the above factors, Diamyd Medical AB (publ) gets an overall score of 1/5.

ISIN	SE0005162880
CurrencyCode	EUR
Exchange	F
Industry	Biotechnology
Sector	Healthcare

Market Cap	128M
Beta	1.9
Target Price	19
PE Ratio	None
Dividend Yield	0.0%

ABOUT

Diamyd Medical AB (publ)

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in Type 1 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.

DMN.F · Diamyd Medical AB (publ)

-

Diamyd Medical AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Diamyd Medical AB (publ) using a moving average strategy